Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
viaminate
- Development stage
- Unknown
- Lead developer
- Chongqing Huapont Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Viaminate is an orally active, first-generation synthetic retinoid (retinoic acid derivative) developed in China by the Institute of Materia Medica, Chinese Academy of Medical Sciences. Chemically, it is an amide compound formed by tretinoin (all-trans retinoic acid) and ethyl p-aminobenzoate. Viaminate acts as an agonist of retinoic acid receptors (RAR) and retinoid X receptors (RXR), regulating epithelial cell growth, differentiation, and proliferation. It is widely approved and marketed in China for the treatment of moderate to severe acne vulgaris, as well as other keratinization disorders such as ichthyosis, psoriasis, and lichen skin diseases. Viaminate reduces sebum secretion, inhibits the keratinization of the sebaceous gland duct epithelium, and exerts anti-inflammatory and immunomodulatory effects, with a milder side-effect profile compared to all-trans retinoic acid.
- Brand names
- BangliSanrui
- Other names
- ethyl 4-(retinoylamino)benzoateN-(4-ethoxycarbonylphenyl) retinamideN-(4-ethoxycarbonylphenyl) vitamin A amideN-[4-(ethoxycarbonyl)phenyl]-retinamideretinamidoester
02
Targets
RAR (Retinoic acid receptor)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on viaminate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on viaminate.